Susan B. Bressler, M.D.

Contact Information:
Maumenee 229
Johns Hopkins Hospital
600 North Wolfe Street
Baltimore, MD 21287-9228

Phone: 410-955-3648
FAX: 410-614-3011
e-mail:  khansbe@jhmi.edu

EDUCATION

High School: Stuyvesant High School, New York, New York

Undergraduate: Smith College, Northampton, MA - Bachelor of Arts: Microbiology - 1978 (Summa cum laude)

Medical School: The Johns Hopkins University School of Medicine, Baltimore, MD - M.D. 1982 (Alpha Omega Alpha)

Internship/Internal Medicine Fellowship: Johns Hopkins Hospital - Department of Medicine, Baltimore, MD - 1982-1983

Ophthalmology Residency: Harvard Medical School and Massachusetts Eye and Ear Infirmary, Boston, MA - 1983-1986

Retinal Fellowship: Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD - 1986-1987

BOARD CERTIFICATIONS

Ophthalmology - October 27, 1987

ACADEMIC APPOINTMENTS AND POSITIONS

1987 - 1988: Instructor of Ophthalmology, Harvard Medical School, Department of Ophthalmology

1988 - 1992: Assistant Professor of Ophthalmology, Johns Hopkins University School of Medicine, Department of Ophthalmology

1992 - 2000: Associate Professor of Ophthalmology, Johns Hopkins University School of Medicine, Department of Ophthalmology

2000 - 2004: Professor of Ophthalmology Johns Hopkins University School of Medicine, Department of Ophthalmology

2004 - : The Julia G. Levy, PhD. Professor of Ophthalmology, Johns Hopkins University School of Medicine, Department of Ophthalmology Inaugural Recipient

1997 - : Director, Wilmer Photograph Reading Center, Johns Hopkins University School of Medicine, Department of Ophthalmology

HOSPITAL APPOINTMENTS

1987 - 1988: Massachusetts Eye and Ear Infirmary, Assistant in Ophthalmology

1988 - 1992: Johns Hopkins Hospital, Assistant Professor of Ophthalmology

1992 - 2000: Johns Hopkins Hospital, Associate Professor of Ophthalmology

1988 - 1993: Sinai Hospital, Consultant Staff

1992 - 2000: Department of Surgery, Division of Ophthalmology, Johns Hopkins Bayview Medical Center, Associate Staff

2000 - present: Johns Hopkins Hospital, Professor of Ophthalmology

HONORS

1975 - 1978: Dean's List Smith College

1976: First Group Scholar Smith College

1977: Phi Beta Kappa

1978: Summa Cum Laude Smith College

1981: Alpha Omega Alpha Johns Hopkins University School of Medicine

1982: Paul Ehrlich Award in Clinical Investigation Johns Hopkins University School of Medicine

1982: Citation for Scholastic Achievement American Medical Women's Association

1986: Heed Fellowship

1987: Heed/Knapp Fellowship

1995: American Academy of Ophthalmology Honor Award

1998: Research to Prevent Blindness Olga Keith Wiess Scholar

2000: Inaugural recipient of the Neil Miller Medical Student Teaching Award

2000: 29th Jean Lacerte Lecture; Photodynamic therapy for AMD. Les Journees Ophtalmologiques De L?Universite Laval, Quebec City, CANADA

2001: Women to Watch Award (Jewish Women Magazine)

2002: The Paul Sternberg, Jr. Lectureship, Emory University, Atlanta, Georgia

2002: Rosenthal Award (Macula Society)

2003: The Krill Lecture, Chicago Ophthalmological Society, Chicago, Illinois

2003: First Louisville Academy of Ophthalmology Memorial Lectureship, Louisville, Kentucky

2004: The Helen Keller Lecture, 2004, University of Alabama at Birmingham

2004:  Honor Award, The American Society of Retina Specialists

2004: The American Academy of Ophthalmology Senior Achievement Award

PEER-REVIEWED PUBLICATIONS

1. Bressler SB, Bressler NM, Fine SL et al: Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol 93:157-163, 1982.
2. Fine SL, Bressler NM, Bressler SB, Murphy RP: Macular degeneration update 1983. Trans Pac Coast Oto-Ophthalmol Soc 63: 35-40, 1982.
3. Bressler SB, Bressler NM, Fine SL et al: Subfoveal neovascular membranes in senile macular degeneration: Relationship between membrane size and visual prognosis. Retina 3:7-11, 1983.
4. Weiss JS, Bressler SB, Jacobs EF Jr et al: Maxillary amelioblastoma with orbital invasion. Ophthalmology, 92:710-713, 1985.
5. Bressler NM, Bressler SB, Gragoudas EG: Clinical characteristics of choroidal neovascular membranes. Arch Ophthalmol, 105:209-213, 1987.
6. Bressler NM, Bressler SB, Fine SL: Age-related macular degeneration. Surv Ophthalmol, 32:375-413, 1988.
7. Bressler SB, Bressler NM, Seddon JS, et al: Interobserver and intraobserver reliability in the clinical classification of drusen. Retina, 8:102-108, 1988.
8. Bressler NM, Bressler SB, Seddon JS et al: Drusen characteristics in patients with exudative versus non-exudative age-related macular degeneration. Retina, 8:109-114, 1988.
9. Bressler NM, Frost L, Bressler SB, Fine SL: Natural course of poorly defined choroidal neovascularization in macular degeneration. Arch Ophthalmol, 106:1537- 1542, 1988.
10. Bressler NM, Bressler SB, West S et al: The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol, 107:847-852, 1989.
11. Sunness JS, Massof RW, Bressler NM, Bressler SB: Diminished foveal sensitivity may predict the development of advanced age-related macular degeneration. Ophthalmology, 96:375-381, 1989.
12. West S, Bressler NM, Bressler SB et al: Exposure to sunlight and other risk factors associated with age-related macular degeneration. Arch Ophthalmol, 107:875-879, 1989.
13. Sunness JS, Massof RW, Bressler NM, Bressler SB: S cone pathway sensitivity in eyes with high risk and low risk drusen characteristics. Applied Optics, 28:1158-1164, 1989.
14. Macular Photocoagulation Study Group: Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Arch Ophthalmol, 107:344-352, 1989.
15. Chamberlin JA, Bressler NM, Bressler SB, et al: The use of fundus photographs and fluorescein angiograms in the identification and treatment of chorodial neovascularization in the Macular Photocoagulation Study. Ophthalmology, 1526-1534, 1989.
16. Maguire MG, Folk JC, Singerman LJ, Schachat AP, Blackhurst DW, Chamberlin JA, Bressler NM, Fine SL, Hawkins BS, Elman MJ, Macular Photocoagulation Study Group: Response t Partial ablation of neovascular membranes involving the fovea. Arch Ophthalmol, 107:955-956, 1989.
17. Macular Photocoagulation Study Group: Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 108:816-824, 1990.
18. Macular Photocoagulation Study Group: Krypton laser photocoagulation for idiopathic neovascular lesions: results of a randomized clinical trial. Arch Ophthalmol 108:832-837, 1990.
19. Macular Photocoagulation Study Group: Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Arch Ophthalmol 108:825-831, 1990.
20. Bressler SB, Maguire MG, Bressler NM et al: Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. Arch Ophthalmol, 108:1442-1447, 1990.
21. Taylor HR, Munoz B, West S, Bressler NM, Rosenthal FS, Bressler SB: Visible light and risk of age-related macular degeneration. Tr Am Ophth Soc, 88:163- 178, 1990.
22. Bressler NM, Bressler SB, Alexander J, et al: Loculated fluid: A previously undescribed angiographic finding in macular degeneration. Arch Ophthalmol, 109:211- 215, 1991.(Although listed as second author, the concept, execution, analysis, and manuscript preparation of this project was equally shared by the first and second author.)
23. Kwiterovich KA, Fine SL, Maguire MG, Bressler NM, Bressler SB, Murphy RP: Fluorescein angiography: frequency of adverse reactions. Ophthalmology, 98:1139-1142, 1991.
24. Macular Photocoagulation Study Group: Argon laser photocoagulation for neovascular maculopathy after five years. Results from randomized clinical trials. Arch Ophthalmol 109:1109-1114, 1991.
25. Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: Results of a randomized clinical trial. Arch Ophthalmol, 109:1219-1230, 1991.
26. Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration: Results of a randomized clinical trial. Arch Ophthalmol, 109:1232-1241, 1991.
27. Bressler NM, Alexander JA, Bressler SB et al: Subfoveal neovascular lesions in age-related macular degeneration: Guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol, 109:1242-1257, 1991.
28. Folk JC, Blackhurst DW, Alexander J, Elman MJ, Phillips DA, Macular Photocoagulation Study Group: Pretreatment fundus characteristics as predictors of recurrent choroidal neovascularization. Arch Ophthalmol, 109:1193-1194, 1991.
29. Taylor HR, West S, Munoz B, Rosenthal FS, Bressler SB, Bressler NB: The long-term effects of visible light on the eye. Arch Ophthalmol, 110:99-106, 1992.
30. Bressler SB, Silva JC, Bressler NM, Alexander JA, Green WR: Clinicopathologic correlation of occult choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol, 110:827-832, 1992.
31. Lim JI, Bressler NM, Marsh MJ, Bressler SB: Laser treatment of choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol, 116:414-423, October, 1993.
32. Bressler NM, Alexander J, Hawkins BS, Maguire MG, Fine SL, Macular Photocoagulation Study Group: Response t Subfoveal neovascular lesions in age- related macular degeneration. Arch Ophthalmol, 111:901, 1993.
33. Burgess DB, Hawkins BS, Jefferys J, Bressler NM, Bressler SB: Macular Photocoagulation Study Group: Five-year follow-up of fellow eyes of patients with age- related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol, 111:1189-1199, 1993.
34. Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: Updated findings from two clinical trials. Arch Ophthalmol, 111:1200-1209, 1993.
35. Dastgheib K, Bressler SB, Green WR: Clinicopathologic correlation of laser lesion expansion following treatment of choroidal neovascularization. Retina, 13:345- 352, 1993.
36. West S, Vitale S, Hallfrisch J, Munoz B, Muller D, Bressler SB, Bressler NM: Are antioxidants or supplements protective for age-related macular degeneration. Arch Ophthalmol, 112:222-227, 1994
37. Bressler NM, Silva J, Bressler SB, Fine SL, Green WR: Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. Retina, 14:130-142, 1994.
38. Macular Photocoagulation Study Group: Laser photocoagulation of juxtafoveal choroidal neovascularization: Five-year results from randomized clinical trials. Arch Ophthalmol 111:500-509, 1994.
39. Maguire MG, Fine SL, Folk JC, Bressler NM, et al. for the Macular Photocoagulation Study Group: Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: The influence of initial lesion size and initial visual acuity. Arch Ophthalmol 112:480-488, 1994.
40. Macular Photocoagulation Study Group: Persistent and recurrent choroidal neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Arch Ophthalmol 112:489- 499, 1994.
41. Pieramici DJ, Bressler NM, Bressler SB, Schachat AP: Choroidal neovascularization in black patients. Arch Ophthalmol, 112:1043-1046, 1994.
42. Bressler SB, Jefferys JL, Bressler NM, Alexander J, et al, for the Macular Photocoagulation Study Group: Evaluation of argon green versus krypton red laser for photocoagulation of subfoveal choroidal neovascularization in the Macular Photocoagulation Study. Arch Ophthalmol, 112:1176-1184, 1994.
43. Sykes SO, Bressler NM, Maguire MG, Schachat AP, Bressler SB: Detecting recurrent choroidal neovascularization: Comparison of clinical examination with and without fluorescein angiography. Arch Ophthalmol, 112:1561-1566, 1994.
44. Edwards MG, Schachat AP, Bressler SB, Bressler NM: Outcome of cataract surgery performed to permit diagnosis, determine eligibility for laser therapy, or perform laser therapy of retinal disorders. Am J Ophthalmol, 118(4):440-444, 1994.
45. Macular Photocoagulation Study Group: Laser photocoagulation for neovascular lesions nasal to the fovea associated with ocular histoplasmosis or idiopathic causes. Arch Ophthalmol, 113:56-61, 1995.
46. Macular Photocoagulation Study Group: The influence of treatment coverage on the visual acuity of eyes treated with krypton laser for juxtafoveal choroidal neovascularization. Arch Ophthalmol, 113:190-194, 1995.
47. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, et al: An international classification and grading system for age-related maculopathy and age- related macular degeneration. The International AMD Epidemiological Study Group. Surv Ophthalmol 39:5:367-374, 1995.
48. Bressler NM and Bressler SB: Preventive Ophthalmology: Age-related macular degeneration. Ophthalmology, 102:1206-1211, 1995.
49. Dyer DS, Brant AM, Schachat AP, Bressler SB, Bressler NM: Angiographic features and outcome of questionable recurrent choroidal neovascularization. Am J Ophthalmol, 120(4):497-505, 1995.
50. Duncan DD, Schneider W, West KJ, Kirkpatrick SJ, West SK, and the Salisbury Eye Evaluation Project Team: The development of personal dosimeters for use in the visible and ultraviolet wavelength regions. Photochem Photbiol, 62:94-100, 1995.
51. Bressler NM, Marsh MJ, Maguire MG, Alexander J, Phillips DA, Javornik NB, Heiner CJ, Bressler SB et al for the MPS Group: Occult choroidal neovascularization: Influence on visual outcome in patients with age-related macular degeneration. Arch Ophthalmol, 114:400-412, 1996.
52. Wilkinson CP, Hawkins BS, Javornik NB, Newhouse MM, Bressler NM, Bressler SB et al for the MPS Group: Five-year follow-up of fellow eyes of individuals with ocular histoplasmosis and unilateral extrafoveal or juxtafoveal choroidal neovascularization. Arch Ophthalmol, 114:677-688, 1996.
53. Kiri A, Dyer DS, Bressler NM, Bressler SB, Schachat AP: Detection of diabetic macular edema: Nidek 3Dx stereo photography compared with fundus biomicroscopy. Am J Ophthalmol, 122:5:654-662, 1996.
54. Bressler NM, Maguire MG, Murphy PL, Alexander J, Margherio R, Schachat AS, Fine SL, Stevens TS, Bressler SB: Macular scatter ('grid') laser treatment of poorly demarcated subfoveal choroidal neovascularization in age-related macular degeneration: Results of a randomized pilot trial. Arch Ophthalmol, 114:1456-1464, 1996.
55. Stevens TS, Bressler NM, Maguire MG, Bressler SB, Fine SL, et al: Occult choroidal neovascularization in age-related macular degeneration: A natural history study of morphologic changes. Arch Ophthalmol, 115:345-350, 1997.
56. West SK, Munoz B, Rubin GS, Schein O, Bandeen-Roche K, Zeger S, German P, Fried L, and the SEE Project Team: Function and vision impairment in a population-based study of older adults. Invest Ophthalmol Vis Sci, 38:72-82, 1997.
57. Duncan DD, Munoz B, Bandeen-Roche K, West SK, and the Salisbury Eye Evaluation Project Team: Visible and ultraviolet-B ocular-ambient exposure ratios for a general population. Invest Ophthalmol Vis Sci , 38:5:1003-1011, 1997.
58. West S, Rubin G, Munoz B, Abraham D, Fried LP, and Salisbury Eye Evaluation Project Team: Assessing functional status: Correlation between performance on tasks conducted in a clinic setting and performance on the same task conducted at home. J Gerontol, 52a:4:M209-M217, 1997.
59. Pharmacological Therapy for Macular Degeneration Study Group: Interferon Alfa-2a is ineffective for patients with choroidal neovascularization secondary to age- related macular degeneration: results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol 115:865-72, 1997.
60. Rubin GS, West SK, Munoz B, Bandeen-Roche K, et al., for the SEE Project Team: A comprehensive assessment of visual impairment in an older American population: SEE Study. Invest Ophthalmol Vis Sci, 38:557-568, 1997.
61. Maguire MG, Bressler SB, Bressler NM, Alexander J, et al for the Macular Photocoagulation Study Group: Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol, 115:741-747, 1997.
62. Duncan DD, Munoz B, Bandeen-Roche K, West SK, and Salisbury Eye valuation Project Team: Assessment of ocular exposure to ultraviolet-B for population studies. Photochem and Photobiol, 66[5]:701-709, 1997.
63. Grossniklaus HE, Green WR for the Submacular Surgery Trials Research Group: Histopathologic and ultrastructural findings of surgically excised choroidal neovascularization. Arch Ophthalmol, 116:745-749, 1998.
64. Rosberger DF, Schachat AP, Bressler SB, Bressler NM: Availability of color fundus photographs from previous visit affects practice patterns for patients with diabetes mellitus. Arch Ophthalmol, 116:1607-1610,1998.
65. Weisz JM, Bressler NM, Bressler SB, Schachat AS: Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract surgery.   Ophthalmology,106:1656-1659, 1999.
66. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of two randomized clinical trials -- TAP Report No. 1.   Arch Ophthalmol ,117;1329-1345, 1999.
67. Age-Related Eye Disease Study Research Group: The Age-Related Eye Disease Study (AREDS): Design implications. AREDS Report No. 1.  Controlled Clinical Trials, 20:573-600,1999.
68. Age-Related Eye Disease Study Research Group: The Age-Related Eye Disease Study: A clinical trial of zinc and antioxidants -- AREDS Report No. 2.  J Nutr, 130:1516S-1519S, 2000.
69. Age-Related Eye Disease Study Research Group: Risk factors associated with age-related macular degeneration: A case-control study in the Age-Related Eye Disease Study: AREDS Report No. 3.  Writing team:  Anand R, Bressler SB, Davis MD,  Ferris FL, Klein R, Lindblad AS, Milton RC, Sperduto RD. Ophthalmology,107:2224-2232, 2000.
70. Bressler NM, Bressler SB: Photodynamic therapy with Verteporfin (Visudyne): Impact on Ophthalmology and Visual Sciences.  Investigative Ophthalmology and Visual Sciences, 41:3;624-628, 2000.
71. Munoz B, West SK, Rubin GS, Schein OD, Quigley HQ, Bressler SB, Fried L, Bandeen-Roche, K, and SEE Study Team: Causes of blindness and visual impairment in a population of older Americans: The SEE Study.  Arch Ophthalmol, 118:819-825, 2000.
72. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Vertoporfin: Two-year results of two randomized clinical trials -- TAP Report No. 2.  Arch Ophthalmol, 119:198-207, 2000.
73. Bressler NM, Bressler SB, Cotch MF, Hawkins BS, Marsh MJ, et al for  The Submacular Surgery Trials Pilot Study Investigators: Submacular Surgery Trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration. I. Ophthalmic outcomes. SST Pilot Study Report No. 1.  Am J Ophthalmol, 130:4:387-407, 2000.          
74. Submacular Surgery Trials Pilot Study Investigators: Submacular Surgery Trials randomized pilot trial of laser versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration. II. Quality of life outcomes.  SST Pilot Study Report No. 2. Am J Ophthalmol, 130:4:408-418, 2000.
75. Age-Related Eye Disease Study Research Group: The Age-Related Eye Disease Study (AREDS) system for classifying cataracts from photographs:  AREDS Report No. 4.  Am J Ophthalmol, 131:167-175, 2001.
76. Age-Related Eye Disease Study Research Group:  Risk factors associated with age-related nuclear and cortical cataract: A case control study in the Age-Related Eye Disease Study. AREDS Report No. 5.  Ophthalmology, 108:1400-1408, 2001.
77. Age-Related Eye Disease Study Research Group: The AREDS system for classifying age-related macular degeneration from photographs. AREDS Report No. 6.  Am J Ophthalmol, 132:668-681, 2001.
78. Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss.  AREDS Report No. 8. Arch Ophthalmol 119:1417-1436, 2001.
79. The Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled clinical trial of high-dose antioxidant supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss. AREDS Report No. 9. Arch Ophthalmol, 119:1439-1452, 2001.
80. Verteporfin in Photodynamic Therapy (VIP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization and pathologic myopia with Verteporfin: One-year results of a randomized clinical trial --  VIP Report No. 1.  Ophthalmology, 108:841-852, 2001.
81. Verteporfin In Photodynamic Therapy (VIP) Study Group: Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration: Two-Year Results of a Randomized Clinical Trial Including Lesions with Occult with No Classic Choroidal Neovascularization -- VIP Report No. 2.  Am J Ophthalmol, 131:5:541-560, 2001.
82. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Study Group Principal Investigators, and Verteporfin in Photodynamic therapy (VIP) Study Group Principal Investigators: Guidelines for using Verteporfin (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes.  Retina, 22:6-18, 2002.
83. The Age-Related Eye Disease Study Research Group: The effect of five-year zinc supplementation on serum zinc, serum cholesterol and hematocrit in persons randomly assigned to treatment group in the Age-Related Eye Disease Study: AREDS Report No. 7. J. Nutr. 132:697-702, 2002.
84. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Three-year results of an open-label extension of 2 randomized clinical trials -- TAP Report No. 5. Arch Ophthalmol, 120:1307-1314, 2002.
85. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Verteporfin Visudyne therapy of additional choroidal neovascularization in age-related macular degeneration: Additional information regarding baseline lesion composition?s impact on vision outcomes -- TAP Report No. 3. Arch Ophthalmol, 120:1443-1454, 2002.
86. Rubin GS, Bressler NM and the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Effects of verteporfin therapy on contrast sensitivity: Results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation-- TAP Report No. 4. Retina, 22:536-544, 2002.
87. Saperstein DA, Rosenfeld PJ, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmol 109:1499-1505, 2002.
88. Clemens TE, Chew EY, Bressler SB, McBee W for the AREDS Research Group: National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS). Report No. 10. Arch Ophthalmol 121:211-217, 2003.
89. Ladd BS, Solomon SS, Bressler NM, Bressler SB: Photodynamic therapy with verteporfin for choroidal neovascularization in patients with diabetic retinopathy. Am J Ophthalmol, 132:5:659-667, 2003.
90. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group and Verteporfin in Photodynamic Therapy (VIP) Study Groups: Effect of baseline lesion size, visual acuity, and lesion composition on visual acuity change with and without Verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP Report No. 1. Am J Ophthalmol 136:407-418, 2003.
91. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group and Verteporfin in Photodynamic Therapy (VIP) Study Groups: Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: Fluorescein angiographic guidelines for evaluation and treatment. TAP and VIP Report No. 2. Arch Ophthalmol, 121:1253-1268, 2003.
92. Mimouni KF, Bressler SB, Bressler NM: Photodynamic therapy for Subfoveal choroidal neovascularization in children. Am J Ophthalmol, 135(6):900-2, 2003.
93. Verteporfin in Photodynamic Therapy (VIP) Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: Two-year results of a randomized clinical trial -- VIP Report No. 3. Ophthalmology, 110(4): 667-73, 2003.
94. DiLoreto DA, Bressler, NM, Bressler SB, Schachat AP: Best and final visual acuity in ophthalmologic research. Arch Ophthalmol, 121:1586-1590, 2003.
95. Age-Related Eye Disease Study Research Group: Potential public health impact of AREDS Results: AREDS report No. 11. Arch Ophthalmol, 121:1621-1624, 2003.
96. Japanese Age-Related Macular Degeneration Trial (JAT) Study Group: Japanese Age-related macular degeneration Trial (JAT): One-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 136:1049-1061, 2003.
97. The Submacular Surgery Trials Research Group: Responsiveness of the National Eye Institute Visual Function Questionnaire to Changes in Visual Acuity: Findings in patients with subfoveal choroidal neovascularization: SST Report No. 1. Arch Ophthalmol, 121: 531 - 539, 2003.
98. Childs AL and the Submacular Surgery Trials Patient-Centered Outcomes Subcommittee for the Submacular Surgery Trials Pilot Study Investigators: Responsiveness of the SF-36 Health Survey to changes in visual acuity among patients with subfoveal choroidal neovascularization. Am J Ophthalmol 137: 373 - 375, 2004.
99. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Meta-analysis of 2-year safety results in three randomized clinical trials: TAP and VIP Report No. 4. Retina, 24:1-12, 2004.
100. Do DV, Bressler NM, Bressler SB: Large Submacular hemorrhages after verteporfin therapy. Am J Ophthalmol 137: 558-560, 2004.
101. Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, and Bressler NM: Detection of diabetic foveal edema: Contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol 122:330-335, 2004.
102. Bressler SB, Pieramici DJ, Koester MS, Bressler NM for the Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: Outcomes potentially relevant to management. TAP Report No. 6. Arch Ophthalmol, 122:325-329, 2004.
103. Age-Related Eye Disease Study Research Group: Mortality in the Age-Related Eye Disease Study: Associations with ocular disorders and an intervention of high-dose antioxidants and zinc. AREDS Report No. 13. In press, Arch Ophthalmol, 2004.
104. Blair MP, Apte R, Bressler NM, Miskala P, Schachat AP, Bressler SB, Goldberg MF: A retrospective case series of juxtafoveal choroidal neovascularization treated with photodynamic therapy with Verteporfin. In press, Retina, 2004.
105. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups: Review of acute severe visual acuity decrease following photodynamic therapy with verteporfin: Case reports from randomized clinical trials. TAP and VIP Report No. 3. Submitted, Am J Ophthalmol, May, 2004.
106. Visudyne in Minimally Classic CNV (VIM) Study Group: Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: One-year results of a randomized clinical trial. Submitted, Arch Ophthalmol, 2004.
107. The Submacular Surgery Trials Research Group: Effect of order of
     administration of health-related quality of life interview instruments on responses - Submacular Surgery Trials Report No. 3. Submitted, Quality of Life Research, 2004.
108. The Age-Related Eye Disease Study Research Group: A randomized, controlled trial of antioxidants and zinc and the impact on cognition in the elderly: The AREDS Ancillary Study. AREDS Report No. 12. Submitted, 2004.
109. The Age-Related Eye Disease Study Research Group: Responsiveness of the NEI-VFQ to progression to advanced AMD, vision loss, lens opacity, and cataract surgery. AREDS report No. 14. Submitted, 2004.
110. Bressler SB, Munoz B, Solomon SD, West SK, and the Salisbury Eye Evaluation (SEE) Study Team: Racial differences in the Prevalence of age-related macular degeneration: The Salisbury Eye Evaluation (SEE) Project. Submitted, Arch Ophthalmol, September, 2004.
111. The Submacular Surgery Trials (SST) Research Group:  Surgery for subfoveal choroidal neovascularization in Age-Related Macular Degeneration:  Quality-of-Life findings:  SST Report No. 12.  Ophthalmol 2004;111:1981-1992. 
112. The Submacular Surgery Trials (SST) Research Group:  Surgery for hemorrhagic choroidal neovascular lesions of Age-Related Macular Degeneration:  Ophthalmic findings:  SST Report No. 13.  Ophthalmol 2004; 111:1993-2006.
113. The Submacular Surgery Trials (SST) Research Group:  Surgery for hemorrhagic choroidal neovascular lesions of Age-Related Macular Degeneration:  Quality of Life findings:  SST Report No. 14.  Ophthalmol 2004; 111:2007-2014
114. Rosenfeld PJ, Saperstein DA, Bressler NM, et al.  Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome:  two-year results of an uncontrolled, open-label clinical study.  In press, Ophthalmology 2004.The Submacular Surgery Trials Research Group:  Histopathological and ultrastructural features of surgically-excised subfoveal choroidal neovascular lesions:  SST Report No. 7.  In press, Arch Ophthalmol, 2004.
115. The Salisbury Eye Evaluation (SEE) Study Team:  Hormone replacement therapy, reproductive factors, and age-related macular degeneration:  The Salisbury Eye Evaluation Project.  In press, Ophthalmic Epidemiology, 2004.
116. Visudyne in Minimally Classic CNV (VIM) Study Group:  Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration:  One-year results of a randomized clinical trial. Submitted, Arch Ophthalmol, 2004.
117. The Submacular Surgery Trials Research Group:  Effect of order of administration of health-related quality of life interview instruments on responses - Submacular Surgery Trials Report No. 3.    Submitted, Quality of Life Research, 2004.
118. The Age-Related Eye Disease Study Research Group:  A randomized, controlled trial of antioxidants and zinc and the impact on cognition in the elderly:  The AREDS Ancillary Study. AREDS Report No. 12.  Submitted, 2004.
119. The Age-Related Eye Disease Study Research Group:  Responsiveness of the NEI-VFQ to progression to advanced AMD, vision loss, lens opacity, and cataract surgery.  AREDS report No. 14.  Submitted, 2004.
120. Bressler SB, Munoz B, Solomon SD, West SK, and the Salisbury Eye Evaluation (SEE) Study Team:  Racial differences in the Prevalence of age-related macular degeneration:  The Salisbury Eye Evaluation (SEE) Project.  Submitted to Arch Ophthalmol,  2004.
121. The Age-Related Eye Disease Study Research Group:  Risk factors associated with the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS).  AREDS Report No. 19.  Submitted to Ophthalmology, 2004.
122. The Age-Related Eye Disease Study Research Group:  The Age-Related Eye Disease Study severity scale for age-related macular degeneration.  AREDS Report No. 18.  Submitted to Arch Ophthalmol, June 2004.
123. Verteporfin in Photodynamic Therapy (VIP) Study Group: Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: Clinical relevant natural history information from the Verteporfin in photodynamic therapy (VIP) Trial -VIP Report No. 4.  Submitted toArch Ophthalmol, June 2004.

124. Hwang T, Bressler SB, Schachat AP, Bressler NM:  Choroidal neovascularization in Asians.  Submitted to AJO, November, 2004.

INVITED EDITORIALS

1. Bressler SB: Does wavelength matter when photocoagulating eyes with macular degeneration or diabetic retinopathy? (Invited Editorial). Arch Ophthalmol, 111:177-180, 1993.
2. Bressler NM, Bressler SB:ICG Angiography: Can it help preserve our patients' vision? (Invited Editorial) Arch Ophthalmol, 114:747-749, 1996.(This article was a joint endeavor of equal portions between Drs. S. and N. Bressler.)
3. Bressler SB, Bressler NM: Randomized Clinical Trials in Ophthalmology in 2001: 25th Anniversary of the First Publication from the Diabetic Retinopathy Study.  Am J Ophthalmol, 131:4:503-504, 2001.
4. Bressler SB, Diener-West M, Taylor HR, Straatsma BR: Clinical Trials Digest on the internet at AJO.com: Entering a new information age.  Am J Ophthalmol, 132:4:566-567, 2001.
5. Bressler NM, Hawkins BS, Sternberg P, McDonald HR, for the Submacular Surgery Trials Research Group: Are the Submacular Surgery Trials (SST) still relevant in an era of photodynamic therapy?  Ophthalmology, 108:435-436, 2001.
6. Straatsma BR, Aaberg TM, Bressler SB, Holland GN, Kaiser PK, Lewis H, Liesegang TJ, Miller NR, Pepose JS, Spivey B: Internet Advance: Accelerated internet publication of articles and reports on AJO.com.  Am J Ophthalmol, 133:551, 2002.

CORRESPONDENCE

1. Fine SL, Hawkins BS, Maguire MG and the Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Arch Ophthalmol, 109:614-615, 1991.
2. Bressler SB: Does wavelength matter when photocoagulating eyes with macular degeneration or diabetic retinopathy? In reply. Arch Ophthalmol, 112:157, 1994.
3. West SK, Bressler SB, Bressler NM, Vitale S: Are antioxidants or supplements protective for age-related macular degeneration? In reply. Arch Ophthalmol, 112:729-730, 1994.
4. Bressler SB: Letter to the Editor re: Laser Therapy for Retinopathy of Prematurity by the Laser ROP Study Group. Arch Ophthalmol, 113:2:137, 1995.
5. Bressler SB: Causes and prevalence of vision impairment in elderly patients: The Salisbury Eye Evaluation.  Audio-Digest in Ophthalmology, Vol. 38, Issue #13, July, 2000.
6. Bressler NM for the Verteporfin in Photodynamic Therapy Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization -- VIP Report No. 2.  Am J Ophthalmol, 133:168-169, 2002. Writing Committee: Letter to the Editor regarding additional data relevant to VIP Report #2.
7. Bressler NM for Verteporfin in Photodynamic Therapy (VIP) Study Group: Response to letter from Ruiz-Oliva and Cortes regarding Verteporfin in photodyamic therapy report No. 1. Ophthalmology, 109:6:1043-1044, 2002.
8. Verteporfin In Photodynamic Therapy (VIP) Study Group: Response to Da Pozzo and Parodi in reference to Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization -- VIP Report 2. In press, Am J Ophthalmol, 2002.
9. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.Improvement after Verteporfin Therapy. Writing Committee: Letter to Editor RE: Treatment of age-related macular degeneration Study Group Reports No. 1 and 2: Arch Ophthalmol 1999;117:1329-1345 and Arch Ophthalmol 2001;119:198-207. Arch Ophthalmol 121:415-416, 2003.

COMMENTARY/DISCUSSIONS (BY INVITATION)/PEER REVIEWED

1. Bressler SB: Age-Related Macular Degeneration Preferred Practice Pattern. Abstracts of Clinical Care Guidelines, 2/5, pp.3-5, Sept/Oct. 1990.
2. Bressler SB: Age-related macular degeneration. Focal Points Module: American Academy of Ophthalmology, XIII:2, March, 1995.
3. Bressler SB, Bressler NB: Commentary: Retinopathy in patients with type I diabetes four years after intensive therapy. Arch Ophthalmol 2000;118:984-985, 2000.

FULL TEXTBOOKS

1. Bressler SB, Brown GL, Flynn HW, Meredith T, Regillio C. American Academy of Ophthalmology¹s Basic Clinical Skills Course Section 12: Retina and Vitreous, 1999 - 2002.

BOOK CHAPTERS

1. Bressler NM, Bressler SB, Berson FG: Ophthalmic agents. In Manual of Drug Therapy. Eds. Scheinberg DA, Scheinberg LC. New York: Raven Press, 1985.
2. Bressler SB, Bressler NM, Murphy RP: Argon laser treatment: randomized clinical trials--short and long term results. In Ocular Circulation and Neovascularization. Eds BenEzra D, Ryan SJ. Boston: Martinus Nijhoff Publishers, 1987.
3. Bressler NM, Bressler SB, Murphy RP, Fine SL: Recurrent choroidal neovascularization following successful photocoagulation in age-related macular degeneration. In Ocular Circulation and Neovascularization. Eds BenEzra D, Ryan SJ. Boston: Martinus Nijhoff Publishers, 1987.
4. Bressler NM, Bressler SB, Murphy RP, Fine SL: Recurrent choroidal neovascularization following successful photocoagulation in age-related macular degeneration. In Laser Photocoagulation of Retinal Disease. Eds Gitter KA, Schatz H, Yannuzzi LA, McDonald HR. San Francisc Pacific Medical Press, 1988.
5. Bressler NM, Bressler SB: Laser treatment of choroidal neovascularization in macular degeneration and presumed ocular histoplasmosis. In Ophthalmology Clinics of North America: Practical Laser Surgery and Its New Frontiers. Ed March WF. Philadelphia: WB Saunders Co, 1989.
6. Boldt C, Bressler NM, Fine SL, Bressler SB: Age-related macular degeneration. Current Opinion in Ophthalmology, 1;III:247-257, 1990.
7. Bressler SB, Bressler NM: Traumatic maculopathy. In Ocular Trauma. Eds, Hersh P, Shingleton B, Kenyon K. St. Louis; Mosby Year Book, 1991.
8. Bressler NM, Bressler SB, Fine SL: Angiographic interpretation of classic and occult choroidal neovascularization. In Medical and Surgical Retina: Advances, Controversies and Management. Eds Lewis H, Ryan S. St. Louis: Mosby Year Book, 1992.
9. Bressler SB, Bressler NM, Gragoudas ES: Age-related macular degeneration: Drusen and geographic atrophy. In Principles and Practice of Ophthalmology. Eds., Albert DM, Jakobiec FA. WB Saunders Company, 1993.
10. Bressler NM, Bressler SB, Gragoudas ES: Age-related macular degeneration: RPE Detachment and Subretinal Neovascularization. In Principles and Practice of Ophthalmology. Eds., Albert DM, Jakobiec FA. WB Saunders Company, 1993.
11. Custis P, Bressler SB, Bressler NM: Laser management of subfoveal choroidal neovascularization in age related macular degeneration. Current Opinion in Ophthalmology, 4;III:7-18, 1993.
12. Neely K, Bressler NM, Bressler SB: Epidemiology, clinical characteristics, and natural history of age-related macular degeneration. In Ophthalmology Clinics of North America: Macular Diseases. Eds., Grossniklaus, HE, Kincaid, MC. WB Saunders Company, 1993.
13. Bressler SB, Bressler NB, Fine SL: Photocoagulation of choroidal neovascularization. In Medical and Surgical Retina: Advances, Controversies and Management. Eds Lewis H, Ryan S. St. Louis: Mosby Year Book, Inc., 1994.
14. Bressler NB, Bressler SB, Fine SL: Angiographic interpretation of eyes with poorly defined choroidal neovascularization including observation and management. In Medical and Surgical Retina: Advances, Controversies and Management. Eds Lewis H, Ryan S. St. Louis: Mosby Year Book, Inc., 1994.
15. Dyer DS, Bressler SB, Bressler NM: The role of laser wavelength in the treatment of vitreoretinal diseases. Current Opinion in Ophthalmology, 5;III:35-43, 1994.
16. Zimmer-Galler I, Bressler NM, Bressler SB: Treatment of choroidal neovascularization: Updated information from the Macular Photocoagulation Study Group Reports. International Ophthalmic Clinics, Little, Brown and Company, 35 (4):37-57, 1995.
17. Bressler SB: Current Controversies in Clinical Management: Choroidal neovascularization following laser treatment of central serous chorioretinopathy. Wilmer Retina Update, 1:1:12-17, 1995.
18. Bressler SB: Current Controversies in Clinical Management: Macroaneurysms: To treat or not to treat? Wilmer Retina Update, 1:2:9-13, 1995.
19. Finkelstein D, Bressler NM, Bressler SB, Schachat, AP: Prospective randomized clinical trials: Extrapolating for an individual case may require careful clinical judgement. (Editorial) Wilmer Retina Update, 1:2:1-2, 1995.
20. Bressler SB: Current controversies in clinical management: Non-arteritic anterior ischemic optic neuropathy and diabetic retinopathy. Wilmer Retina Update, 1:4:9-16, 1995.
21. Bressler SB: Unusual manifestations of common diseases: 18-year follow- up of choroideremia. Wilmer Retina Update, 1:4:17-21, 1995.
22. Bressler SB: Application of recent clinical research to everyday practice: Treatment of subfoveal recurrent choroidal neovascularization: Decision-making when visual acuity is good. Wilmer Retina Update, 1:6:9-16, 1995.
23. Bressler SB: Unilateral idiopathic parafoveolar telangiectasis: Do abnormalities Progress? Is photocoagulation beneficial? Wilmer Retina Update, 2:1:3- 9, 1996.
24. Bressler NB, Bressler SB: Subgroup Analysis: Use with caution (Editorial). Wilmer Retina Update, 2:2:17-18, 1996.
25. Bressler SB: Occult choroidal neovascularization: It's becoming less mysterious. (Editorial) Wilmer Retina Update, 2:4:48-49, 1996.
26. Bressler NM, Bressler SB: Exacerbation of diabetic macular edema after cataract surgery. Wilmer Retina Update, 2:5:70-85, 1996.
27. Bressler SB, Bressler NM: Massive subretinal fluid accumulation after laser photocoagulation of choroidal neovascularization. Wilmer Retina Update 2:6:94-102, 1996.
28. Fekrat S, Bressler NB, Bressler SB: Are antioxidants or other supplements protective for age-related macular degeneration? Current Opinion in Ophthalmology, 7;III:65-72., 1996.
29. Pieramici DJ, Cooney MJ, Bressler SB: Treatment of longstanding diabetic premacular hemorrhage with Nd: YAG membranotomy. Wilmer Retina Update 3:2:27- 31, 1997.
30. Bressler SB, Bressler NM, Finkelstein D: Unusual and controversial retinal treatments. (Editorial) Wilmer Retina Update 3:2:21-22, 1997.
31. O'Connell SR, Bressler SB: Multiple serosanguineous retinal pigment epithelial detachments. Wilmer Retina Update 3:3:55-62, 1997.
32. Bressler SB, Bressler NM: Choroidal neovascularization in central serous chorioretinopathy without prior laser photocoagulation. Wilmer Retina Update 3:5:91- 96, 1997.
33. Pieramici D, Bressler SB, McCormack Sharon: Simultaneous bilateral central retinal vein occlusion. Wilmer Retina Update 3:6:107-113, 1997.
34. O'Connell SR and Bressler SB: Central serous chorioretinopathy in a renal transplant patient. Wilmer Retina Update 3:6:113-120, 1997.
35. Dick JSB and Bressler SB: Unusual case of postoperative phototoxic maculopathy. Wilmer Retina Update 4:4:58-61, 1998.
36. Loewenstein A, Bressler NB, Bressler SB: Epidemiology of age-related RPE disease. In Retinal Pigment Epithelium: Current Aspects of Function and Disease. Eds., Marmor MF, Wolfensberger TJ. New York: Oxford University Press, 1998.
37. Pieramici D, Bressler SB: Age-related macular degeneration: Risk factors for the development of choroidal neovascularization in the fellow eye. Current Opinion in Ophthalmology, 9:3:38-46. Ed. Brown G. Philadelphia: Rapid Science, 1998.
38. Bressler SB and Rosberger D: Non-neovascular age-related macular degeneration. In Retina, Vitreous, Macula: A Comprehensive Text, Eds., Guyer DR, Yannuzzi LA, Chang S, Shields J, Green WR: Saunders Publishing Company, Philadelphia, PA, 1998.
39. Rosberger DF, Bressler NM, Bressler SB: Ophthalmic Surgery: Photocoagulation. Rob & Smith's Operative Surgery, Eds., Carter DC, Russell RCG, Pitt HA, Dudley H, Lee G, Remes P. Stockman L, Ramage D. London: Lippincott- Raven, 1998.
40. Pieramici D and Bressler SB: Fluorescein Angiography: An Invaluable Tool in the Management of Age-Related Macular Degeneration. In Age-Related Macular Degeneration. Eds. Berger J, Fine SL, Maguire M. St. Louis: C.V. Mosby, 1998.
41. Bressler SB, invited review and revisions for Johns Hopkins Symptoms and Remedies: The Complete Home Medical Reference--Revised and Updated New Edition. Chapters: Presbyopia, retinal detachment, retinal vessel occlusion, scleritis and episcleritis, strabismus, uveitis, and iritis. Medical Editor: Simeon Margolis, M.D.; prepared by the editors of the Johns Hopkins Medical Letter Health After 50. REBUS, 1999.
42. Bressler SB and Bressler NM: Neovascular AMD. In Retina, Third Edition. Eds., Ryan SJ, Schachat AP, Wilkinson WP, Glaser B. St. Louis: C.V. Mosby Company, 2001.
43. Bressler SB, Bressler NM, Gragoudas ES: Age-related macular degeneration: Drusen and geographic atrophy. In Principles and Practice of Ophthalmology, 2nd Edition. Eds., Albert DM, Jakobiec FA. WB Saunders Company, 2000.
44. Bressler NM, Bressler SB, Gragoudas ES: Age?related macular degeneration: Choroidal neovascularization. In Principles and Practice of Ophthalmology, 2nd Edition. Eds., Albert DM, Jakobiec FA. WB Saunders Company, 2000.
45. Bressler SB, invited review and revisions for Johns Hopkins Symptoms and Remedies: The Complete Home Medical Reference--Revised and Updated New Edition. Chapters: Age-Related Macular degeneration, retinal vessel occlusion, retinal detachment, presbyopia, eye cancers, refractive disorders, diabetic retinopathy. Medical Editor: Simeon Margolis, M.D.; prepared by the editors of the Johns Hopkins Medical Letter Health After 50. REBUS, 2002.
46. Eye Disorders for The Merck Manual of Geriatrics. Merck Research Laboratories, Division of Merck and Co., Inc. Whitehouse Station, New Jersey. (Dr. S Bressler served as consultant and editor for this chapter.) In press, 2005.
47. Do DV, Bressler SB, Bressler NM: Pathologic Myopia and Choroidal Neovascularization. In Myopia. Eds. B.G. Bietti Foundation's Sixth International Congress. In press, 2005.
48. Bressler SB and Bressler NM: Neovascular AMD. In Retina, Fourth Edition. Eds., Ryan SJ, Schachat AP, Wilkinson WP, Glaser B.  St. Louis: C.V. Mosby Company.  In press, 2005.

EDITORIAL ROLES

Editor:
Clinical Trials Digest @ AJO.Com, American Journal of Ophthalmology: 2000-2005

Associate Editor:
American Journal of Ophthalmology: 2002 - 2004

Editorial Boards:
Retina: 2001 - present
Survey of Ophthalmology: Reviews in Medicine: 1991 - 2000 
Wilmer Retina Update: 1995 - 2000
American Journal of Ophthalmology: 1999 - 2002
EyeNet Magazine (publication of The American Academy of Ophthalmology): 2004 – December, 2005

Ad Hoc Reviewer, 1990 - :

 American Academy of Ophthalmology Ophthalmic Procedures
   Assessment on Photodynamic Therapy for AMD

American Journal of Ophthalmology

Archives of Ophthalmology

British Journal of Ophthalmology

New England Journal of Medicine

Ophthalmic Epidemiology

Ophthalmic Surgery and Lasers

Ophthalmologica

Ophthalmology

Retina

Survey of Ophthalmology

The Medical Letter